AstraZeneca PLC (AZN) Stock Analysis
AstraZeneca PLC is a multinational biopharmaceutical company headquartered in the UK, specializing in the discovery, development, and commercialization of prescription medicines across oncology, cardiovascular, respiratory, and immunology therapeutic areas. Investors research AZN for its diversified drug portfolio, strong pipeline, and exposure to high-growth disease categories.
Get a full AI research report on AZN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does AstraZeneca PLC do?
AstraZeneca generates revenue primarily through the sale of prescription medications across six therapeutic segments: oncology (including Tagrisso, Lynparza, and Enhertu), cardiovascular (Brilinta, Farxiga), respiratory and immunology (Symbicort, Fasenra, Tezspire), renal and metabolism (Farxiga), vaccines and immune (Beyfortus, Synagis), and rare disease treatments (Soliris, Ultomiris). The company operates a global manufacturing and distribution network to deliver these medicines to healthcare systems and patients worldwide.
Bull case
- ✓Strong gross margin of 81.5% indicates pricing power and efficient manufacturing, typical of successful branded pharmaceutical companies with patent-protected assets.
- ✓Forward P/E of 14.7x is substantially lower than trailing P/E of 25.0x, suggesting market expectations for earnings growth as newer drugs mature and pipeline candidates reach commercialization.
- ✓Operating margin of 27.9% demonstrates significant profitability and operational leverage, allowing reinvestment in R&D and shareholder returns despite competitive pressures.
- ✓Diversified therapeutic portfolio across oncology, cardiovascular, respiratory, and rare diseases reduces dependence on any single drug and spreads patent expiration risk.
- ✓Return on equity of 23.5% reflects efficient capital deployment and strong returns to shareholders relative to book value.
Bear case
- ✗High debt-to-equity ratio of 71.8% indicates substantial leverage, which increases financial risk and limits flexibility for acquisitions or weathering revenue downturns.
- ✗Current ratio of 0.91 and quick ratio of 0.70 suggest potential near-term liquidity constraints, as current liabilities exceed current assets.
- ✗Trailing P/E of 25.0x is elevated relative to many peers, and the company must deliver on forward earnings growth expectations to justify current valuation.
- ✗Pharmaceutical companies face ongoing patent expiration risks; loss of exclusivity on major drugs can cause significant revenue declines without successful pipeline advancement.
- ✗Regulatory and reimbursement pressures in key markets (US, Europe) may constrain pricing and market access for new and existing products.
AZN valuation & financial health
AstraZeneca trades at a trailing P/E of 25.0x but a forward P/E of 14.7x, indicating the market is pricing in meaningful earnings growth over the next 12 months. The PEG ratio of 1.31 suggests the stock is trading near fair value relative to expected growth. The company maintains strong profitability with a net margin of 17.2% and ROE of 23.5%, though the high debt-to-equity ratio of 71.8% and below-1.0 current ratio warrant attention to balance sheet management. The dividend yield of 1.88% with a payout ratio of 47% indicates a sustainable, modest income component alongside growth potential.
The bottom line
AstraZeneca presents a mixed profile for investors to evaluate. The company's diversified portfolio, strong margins, and forward earnings growth expectations are offset by elevated leverage, near-term liquidity considerations, and a valuation that depends on pipeline execution. Key factors to monitor include clinical trial results for pipeline candidates, patent expiration timelines for major revenue drivers, debt reduction progress, and regulatory decisions affecting key products. The forward P/E discount to trailing P/E suggests the market is pricing in growth, making execution on that growth critical to valuation sustainability.
Frequently asked questions
What does AstraZeneca PLC do?
AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines across oncology, cardiovascular, respiratory, immunology, vaccines, and rare disease categories. The company operates globally and generates revenue primarily through drug sales to healthcare systems and patients.
Is AZN a good stock to research?
AstraZeneca is a large-cap pharmaceutical company suitable for investors researching exposure to the healthcare and drug manufacturing sectors. Considerations include the company's diversified pipeline, patent expiration risks, leverage levels, and valuation relative to earnings growth expectations.
What are AstraZeneca's main revenue drivers?
Major revenue contributors include oncology drugs (Tagrisso, Lynparza, Enhertu), cardiovascular medicines (Brilinta, Farxiga), and respiratory/immunology products (Symbicort, Fasenra, Tezspire). The company also generates revenue from vaccines, rare disease treatments, and legacy cardiovascular and metabolic products.
Is AZN overvalued at current prices?
The trailing P/E of 25.0x is elevated, but the forward P/E of 14.7x and PEG ratio of 1.31 suggest the market is pricing in future earnings growth. Valuation fairness depends on the company's ability to deliver on pipeline advancement and manage patent expirations.
What are the main risks for AstraZeneca investors?
Key risks include high debt levels (71.8% debt-to-equity), patent expirations on major drugs, regulatory and reimbursement pressures, liquidity metrics below 1.0, and dependence on pipeline success. Competitive pressures in oncology and respiratory markets also pose ongoing challenges.
Does AstraZeneca pay a dividend?
Yes, AstraZeneca pays a dividend with a yield of 1.88% and a payout ratio of 47%, indicating the company distributes less than half of earnings to shareholders while retaining capital for growth and debt management.
Research AZN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.